IVERIC bio Inc

IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

GA is a form of age-related macular degeneration (AMD) that causes irreversible vision loss, affecting approximately 1.5 million people in the United States 1,2 Eric and his mother, Jamey, are sharing their family's story of GA and AMD to raise awareness of the disease NORTHBROOK, Ill. , Sept. 20, 2023 /PRNewswire/ -- Iveric Bio, An Astellas Company (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced a partnership with two-time Emmy® award-winning actor, Eric Stonestreet, to raise awareness about geographic atrophy (GA), a form of age-related macular degeneration (AMD) that causes irreversible vision loss.1 Eric and his mother, Jamey, are sharing how GA and AMD has affected their family to inspire others to learn about the disease and be proactive around their eye health as part of the campaign.

Two-time Emmy® Award-Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic Atrophy (GA)

GATHER2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham IZERVAY 24-month safety data were  consistent with 12-month results , with no new safety signals identified TOKYO, Sept. 18, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive 24-month topline results from the Phase 3 GATHER2 clinical trial evaluating the efficacy and safety of IZERVAY™ (avacincaptad pegol intravitreal solution), a complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

TOKYO , Aug. 18, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced the European Medicines Agency (EMA) has accepted for regulatory review the marketing authorization application (MAA) for avacincaptad pegol (ACP), an investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The Committee for Medicinal Products for Human Use (CHMP) of the EMA will start its review of the MAA under the centralized licensing procedure for all 27 member states of the European Union (EU).

European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy

IZERVAY is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials IZERVAY slowed loss of photoreceptors and disease progression as early as six months GA impacts an estimated 1.5 million people in the U.S. and can cause irreversible vision loss TOKYO , Aug. 5, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced the U.S. Food and Drug Administration (FDA) approved IZERVAY™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) on August 4, 2023. IZERVAY, a new complement C5 inhibitor, is the only approved GA treatment with a statistically significant reduction (p

Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy

Astellas Pharma Inc

TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the acquisition of IVERIC bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio, "Iveric Bio") with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. (the "Acquisition"). The Acquisition was completed on July 11, 2023, US Eastern Time, as follows, and Iveric Bio has become Astellas' wholly-owned subsidiary.

Astellas Completes Acquisition of Iveric Bio

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to 23 newly-hired, non-executive employees.

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of IVERIC bio, Inc. (NasdaqGS: ISEE) to Astellas Pharma Inc. Under the terms of the proposed transaction, shareholders of IVERIC will receive $40.00 in cash for each share of IVERIC that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the co.

IVERIC BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of IVERIC bio, Inc. - ISEE

NEW YORK , May 1, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of IVERIC bio, Inc. ("IVERIC" or the "Company") (NASDAQ: ISEE), in connection with its proposed acquisition by Astellas Pharma Inc.  Under the merger agreement, the Company's shareholders will receive $40.00 in cash for each share of IVERIC owned.  The transaction is valued at approximately $5.9 billion.

SHAREHOLDER ALERT: Weiss Law Investigates IVERIC bio, Inc.

Iveric Bio Inc shares climbed 16% to $38.01 on Monday after the US drugmaker agreed to be acquired by Japan's Astellas Pharma for $40 per share in cash or total consideration of about $5.9 billion.   Iveric's primary asset is avacincaptad pegol (ACP) which is currently in trials for treating geographic atrophy, the advanced stage of macular degeneration, a common cause of vision loss in the elderly.

Iveric Bio stock surges on Astellas Pharma takeover deal

Astellas Pharma snapped up Iveric Bio for $5.9 billion in cash, the companies said Monday in an announcement that sent ISEE stock flying. The post Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma appeared first on Investor's Business Daily.

Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma

First Republic

JPMorgan Chase & Co

Shares of Iveric Bio Inc. jumped 18% after Japan's Astellas Pharma Inc. said it would acquire the biopharmaceutical company for about $5.9 billion, or $40 per share in cash, a nearly 22% premium to Friday's closing price of $32.89 per share.

First Republic sinks after JPMorgan takeover; deal news lifts Iveric stock

Japan's Astellas agrees to pay $40 a share for Iveric, citing the potential of the biopharmaceutical company's ophthalmology programs.

Iveric Bio Stock Surges. It's Being Bought by Astellas for $5.9 Billion.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Iveric bio, Inc. (NASDAQ: ISEE) to Astellas Pharma Inc. for $40.00 per share in cash is fair to Iveric shareholders. Halper Sadeh encourages Iveric shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Iveric and its.

ISEE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Iveric bio, Inc. Is Fair to Shareholders

MILWAUKEE , May 1, 2023 /PRNewswire/ -- Ademi LLP is investigating IVERIC (NASDAQ: ISEE) for possible breaches of fiduciary duty and other violations of law in its transaction with Astellas.  Click here to learn how to join the action https://www.ademilaw.com/case/iveric-bio-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether IVERIC bio, Inc. has obtained a Fair Price in its transaction with Astellas

Astellas Pharma Inc. said Monday that it agreed to acquire Iveric bio Inc. for about $5.9 billion to strengthen its capabilities in the ophthalmology field.

Japan's Astellas Pharma to buy Iveric Bio in deal worth $5.9 billion

TOKYO & PARSIPPANY, N.J.--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and IVERIC Bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio, “Iveric Bio”) today announced that on April 29, 2023 (Japan time), the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio for US$40.00 per.

Astellas Enters Into Definitive Agreement to Acquire Iveric Bio

TOKYO and PARSIPPANY, N.J., April 30, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Iveric bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio, "Iveric Bio") today announced that on April 29, 2023 (Japan time), the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio for US$40.00 per share in cash for a total equity value of approximately US$5.9 billion (the "Acquisition"). In the Acquisition, Iveric Bio will become an indirectly wholly-owned subsidiary of Astellas.

Astellas Enters into Definitive Agreement to Acquire Iveric Bio

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced new findings from exploratory analyses of data for ACP, presented at the 2023 annual meeting of the ARVO in New Orleans.

Iveric Bio Announces New Functional Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trials Presented at ARVO Annual Meeting

Iveric Bio has a promising pipeline of products, including its complement C5 inhibitor, avacincaptad pegol (ACP), which has achieved impressive results in phase 3 clinical trials. The company's recent post-hoc analysis from its GATHER clinical trial program signals up to a 59% reduction in vision loss with ACP compared to sham treatment.

Iveric Bio: ACP Advances As GATHER Results Continue To Impress

Amylyx Pharmaceuticals

Apellis Pharma

Ascendis Pharma

Axsome Therapeutics

Cogint

CTI BioPharma

Mirati Therapeutics

Reata Pharmaceuticals

Seagen

David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 2012).

These Are the Top 10 Holdings of David Kim

IVERIC bio, Inc. (NASDAQ:ISEE ) Q4 2022 Results Conference Call March 1, 2023 8:00 AM ET Company Participants Kathy Galante - Investor Relations Glenn Sblendorio - Chief Executive Officer Pravin Dugel - President Keith Westby - Chief Operating Officer David Carroll - Chief Financial Officer Dhaval Desai - Chief Development Officer Chris Simms - Chief Commercial Officer Tony Gibney - Chief Business and Strategy Officer Conference Call Participants Annabel Samimy - Stifel Ken Cacciatore - Cowen Ellie Merle - UBS Mike Ulz - Morgan Stanley Greg Harrison - Bank of America Eddie Hickman - Guggenheim Securities Kambiz Yazdi - Jeffries Operator Good morning. And welcome to the IVERIC Bio Fourth Quarter 2022 Earnings Conference Call.

IVERIC bio, Inc. (ISEE) Q4 2022 Earnings Call Transcript

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced financial and operating results for the fourth quarter and full year ended Dec. 31, 2022 and provided a general business update.

Iveric Bio Reports Fourth Quarter and Full Year 2022 Operational Highlights and Financial Results

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced an analysis from the ACP GATHER clinical trial program evaluating reduction in vision loss with ACP 2 mg versus sham treatment.

Iveric Bio Announces Vision Loss Reduction Data in Geographic Atrophy from Avacincaptad Pegol GATHER Trials

PARSIPPANY, N.J.--(BUSINESS WIRE)--Iveric Bio announced that the Company will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023.

Iveric Bio to Present at the Cowen 43rd Annual Health Care Conference

PARSIPPANY, N.J.--(BUSINESS WIRE)--IVERIC bio today announced that it will report its fourth quarter and full year 2022 financial and operating results on Wednesday, March 1, 2023.

News for IVERIC bio Inc Stock (ISEE)